Drug company Amgen Inc. will pay the Maryland Medicaid system $856,474 to settle allegations that it illegally marketed and priced drugs used to treat anemia, rheumatoid arthritis and other diseases.
The settlement, announced Friday by Maryland Attorney General Douglas F. Gansler, is part of a $612 million deal Illinois-based Amgen made with the federal government and several other states.
As part of the settlement, Amgen's future marketing practices will also be monitored by the federal government.
Text BUSINESS to 70701 to get Baltimore Sun Business text alerts
We've upgraded our reader commenting system. Learn more
about the new features.
The Baltimore Sun encourages civil dialogue related to our stories; you must register and log-in to our site in order to participate. We reserve the right to remove any user and to delete comments that violate our Terms of Service
. By commenting, you agree to these terms. Please flag inappropriate comments.